Pharmacokinetic/Pharmacodynamic Model of Neutropenia in Real-Life Palbociclib-Treated Patients

Palbociclib is an oral CDK4/6 inhibitor indicated in HR+/HER2- advanced or metastatic breast cancer in combination with hormonotherapy. Its main toxicity is neutropenia. The aim of our study was to describe the kinetics of circulating neutrophils from real-life palbociclib-treated patients. A population pharmacokinetic (popPK) model was first constructed to describe palbociclib pharmacokinetic (PK). Individual PK parameters obtained were then used in the pharmacokinetic/pharmacodynamic (PK/PD) model to depict the relation between palbociclib concentrations and absolute neutrophil counts (ANC). The models were built with a population of 143 patients. Palbociclib samples were routinely collected during therapeutic drug monitoring, whereas ANC were retrospectively retrieved from the patient files. The optimal popPK model was a mono-compartmental model with a first-order absorption constant of 0.187 h−1 and an apparent clearance Cl/F of 57.09 L (32.8% of inter individuality variability (IIV)). The apparent volume of distribution (1580 L) and the lag-time (Tlag: 0.658 h) were fixed to values from the literature. An increase in creatinine clearance and a decrease in alkaline phosphatase led to an increase in palbociclib Cl/F. To describe ANC kinetics during treatment, Friberg’s PK/PD model, with linear drug effect, was used. Parameters estimated were Base (2.92 G/L; 29.6% IIV), Slope (0.0011 L/µg; 28.8% IIV), Mean Transit Time (MTT; 5.29 days; 17.9% IIV) and γ (0.102). The only significant covariate was age on the initial ANC (Base), with lower ANC in younger patients. PK/PD model-based simulations show that the higher the estimated CressSS (trough concentration at steady state), the higher the risk of developing neutropenia. In order to present a risk lower than 20% to developing a grade 4 neutropenia, the patient should show an estimated CressSS lower than 100 µg/L.

[1]  Jean-David Fumet,et al.  Population Pharmacokinetics of Palbociclib in a Real-World Situation , 2021, Pharmaceuticals.

[2]  W. Huisinga,et al.  Therapeutic drug monitoring of oral targeted antineoplastic drugs , 2020, European Journal of Clinical Pharmacology.

[3]  Haihong Shi,et al.  Palbociclib (PD-0332991) pharmacokinetics in subjects with impaired renal function , 2020, Cancer Chemotherapy and Pharmacology.

[4]  Y. Sheng,et al.  Current Therapeutic Progress of CDK4/6 Inhibitors in Breast Cancer , 2020, Cancer management and research.

[5]  M. Spilker,et al.  A physiological model of granulopoiesis to predict clinical drug induced neutropenia from in vitro bone marrow studies: with application to a cell cycle inhibitor , 2020, Journal of Pharmacokinetics and Pharmacodynamics.

[6]  B. Royer,et al.  A simple and fast LC-MS/MS method for the routine measurement of cabozantinib, olaparib, palbociclib, pazopanib, sorafenib, sunitinib and its main active metabolite in human plasma. , 2019, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[7]  M. Whyte,et al.  Alkaline Phosphatase: Discovery and Naming of Our Favorite Enzyme , 2018, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[8]  G. Shapiro,et al.  Characterization of Neutropenia in Advanced Cancer Patients Following Palbociclib Treatment Using a Population Pharmacokinetic‐Pharmacodynamic Modeling and Simulation Approach , 2017, Journal of clinical pharmacology.

[9]  H. Iwata,et al.  PALOMA-3: Phase III Trial of Fulvestrant With or Without Palbociclib in Premenopausal and Postmenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That Progressed on Prior Endocrine Therapy—Safety and Efficacy in Asian Patients , 2017, Journal of global oncology.

[10]  R. Sahoo,et al.  Neutropenia due to palbociclib: A word of caution? , 2016, Indian Journal of Medical and Paediatric Oncology.

[11]  B. Ramaswamy,et al.  Palbociclib: A Novel Cyclin-Dependent Kinase Inhibitor for Hormone Receptor-Positive Advanced Breast Cancer. , 2015, The Annals of pharmacotherapy.

[12]  R. Pazdur,et al.  FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor–Positive, HER2-Negative Metastatic Breast Cancer , 2015, Clinical Cancer Research.

[13]  I. Trocóniz,et al.  Semimechanistic Cell-Cycle Type–Based Pharmacokinetic/Pharmacodynamic Model of Chemotherapy-Induced Neutropenic Effects of Diflomotecan under Different Dosing Schedules , 2015, The Journal of Pharmacology and Experimental Therapeutics.

[14]  I. Treilleux,et al.  [New therapeutical strategies in metastatic hormone-dependent breast cancer]. , 2015, Bulletin du cancer.

[15]  Sohita Dhillon Palbociclib: First Global Approval , 2015, Drugs.

[16]  I. Treilleux,et al.  [New therapeutical strategies in metastatic hormone-dependent breast cancer]. , 2015, Bulletin du cancer.

[17]  Xin Huang,et al.  The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. , 2015, The Lancet. Oncology.

[18]  D. D. Wang,et al.  462PA POPULATION PHARMACOKINETIC (PK) ANALYSIS OF PALBOCICLIB (PD-0332991) IN PATIENTS (PTS) WITH ADVANCED SOLID TUMORS. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  D. Concordet,et al.  Model-Based Approach to Describe G-CSF Effects in Carboplatin-Treated Cancer Patients , 2013, Pharmaceutical Research.

[20]  D R Mould,et al.  Basic Concepts in Population Modeling, Simulation, and Model-Based Drug Development—Part 2: Introduction to Pharmacokinetic Modeling Methods , 2013, CPT: pharmacometrics & systems pharmacology.

[21]  K. Flaherty,et al.  Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer , 2011, Clinical Cancer Research.

[22]  F. Pinguet,et al.  Factors for hematopoietic toxicity of carboplatin: refining the targeting of carboplatin systemic exposure. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  G. Lyman,et al.  Risk models for predicting chemotherapy-induced neutropenia. , 2005, The oncologist.

[24]  Mats O Karlsson,et al.  Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.